Calvin Klein, Inc. Announces Multi-Year Collaboration with The Andy Warhol Foundation for the Visual Arts
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE:PVH), today announced a multi-year partnership with The Andy Warhol Foundation for the Visual Arts, Inc.
Calvin Klein, Inc.’s financial commitment will support the foundation’s endowment from which it distributes grants sustaining the creation, presentation and documentation of contemporary visual art. In turn, Calvin Klein will be granted unprecedented access to the late artist’s works, including many that have not yet been published. The global partnership is effective through 2020 and will extend to licensing projects across various business lines and future activations within the CALVIN KLEIN brand portfolio.
“I am proud that through this licensing agreement with The Andy Warhol Foundation for the Visual Arts, Calvin Klein will be continuing its longstanding commitment to the celebration of American artists and their prolific work,” said Steve Shiffman, Chief Executive Officer, Calvin Klein, Inc. “I look forward to the global rollout of this partnership across multiple levels of the CALVIN KLEIN consumer experience.”
“I’ve come to realize that Warhol’s genius goes much deeper than cheerful Campbell’s Soup paintings,” said Raf Simons, Chief Creative Officer. “He captured all sides of the American experience, including sometimes its darker sides. Warhol’s art tells more truths about this country than you can find almost anywhere else.”
“Warhol’s legacy is not limited to the tremendous influence of his timeless concepts but also through the work of the foundation he established, which has become one of the pre-eminent funders of contemporary art having distributed over $275 million in grants since inception,” said Michael Dayton Hermann, Director of Licensing at the Warhol Foundation. “We are proud that Raf’s visionary work at Calvin Klein will unabashedly embrace all facets of Warhol’s work and generously contribute to the foundation’s endowment.”
The first iteration of the partnership was unveiled in September 2017, with Raf Simons’ Spring 2018 CALVIN KLEIN 205W39NYC runway show. The collection, which is available in stores in January 2018, incorporates a selection of Warhol artworks as placement screen prints. The body of work is intimately connected to the collection’s inspirations of cinema, the dream factory of Hollywood and its depictions of both an American nightmare and the all-powerful American dream. The pieces feature portraits of Warhol intimate and art collector Sandra Brant (1971) and movie star Dennis Hopper (1971), as well as Knives (1981–82), Electric Chair (1964–65), and Ambulance Disaster (1963–64) from Warhol’s Death and Disaster series. The collection also features pieces produced under license and in collaboration with Hopper Goods, a brand inspired by the life and spirit of actor, photographer, and iconoclast Dennis Hopper.
Andy Warhol’s links to fashion dated back to his first years as an artist, when his witty shoe pictures drew eyes to Vogue and Harper’s Bazaar. In the 1970s, the connection became more personal when Warhol befriended a fresh generation of New York designers that of course included Mr. Calvin Klein himself. Klein had set out to capture a new, truly American essence in his creations, and that meshed perfectly with Warhol’s own interests.
Now, 30 years after Warhol’s death, Simons is setting out to renew the relationship between the great American fashion house of CALVIN KLEIN and this greatest of American artists. Thanks to The Andy Warhol Foundation for the Visual Arts, Simons has been forging what he sees as a deep, thoroughgoing collaboration with the undying genius of Warhol, built on the creative ideals that they share. Like Warhol’s art, Simons’ designs for 2018 and beyond are committed to a fearless embrace of the place and the times that we live in.
About Calvin Klein
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $8 billion in 2016 and were distributed in over 110 countries. CALVIN KLEIN employs over 10,000 associates globally. We were acquired by PVH Corp. in 2003.
About PVH Corp.
With a history going back over 135 years, PVH has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. We have over 35,000 associates operating in over 40 countries and over $8 billion in annual revenues. We own the iconic CALVIN KLEIN , TOMMY HILFIGER , Van Heusen , IZOD , ARROW , Speedo *, Warner’s and Olga brands, as well as the digital-centric True & Co. intimates brand, and market a variety of goods under these and other nationally and internationally known owned and licensed brands.
*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.
About The Andy Warhol Foundation for the Visual Arts, Inc.
As the preeminent American artist of the 20th Century, Andy Warhol challenged the world to see art differently. Since its founding in 1987 in accordance with Andy Warhol’s will, The Andy Warhol Foundation has established itself as among the leading funders of contemporary art in the United States having distributed over $275,000,000 in grants supporting the creation, presentation and documentation of contemporary visual arts, particularly work that is experimental, under-recognized or challenging in nature. The foundation’s ongoing efforts to protect and enhance its founder’s creative legacy ensure that Warhol’s inventive, open-minded spirit will have a profound impact on the visual arts for generations to come. Proceeds the foundation receives from licensing projects such as this contribute to the Foundation’s endowment from which it distributes grants. For more information please visit www.warholfoundation.org.
brand handle: @calvinklein
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib15.11.2018 09:30 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx® (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. “Today’s EC approval for the use of Cabometyx ® provides a much needed new option for HCC patients. Until now, physicians in Europe had only one approved therapy for the 2 nd line treatment of this aggressive and difficult-to-treat cancer.1,2 We are proud to offer Cabometyx ® as an innovative treatment that has been shown to extend survival in previously treated patients with HCC,” said Harout Semerjian, Chief Commercial Officer, Ipsen. “This new indication reinforces Ipsen’s commitment to improve patients’ lives through the expansion of the clinical benefit of Cabometyx ® i
Mobidiag nostaa viimeisen €4M erän Euroopan investointipankin €15M rahoituksesta15.11.2018 09:30 | Tiedote
Mobidiag Oy, vahvassa kasvuvaiheessa oleva molekyylidiagnostiikkayhtiö, joka taistelee antibioottiresistenssin leviämistä vastaan, ilmoitti tänään, että se on nostanut viimeisen 4 miljoonan euron erän 15 miljoonan euron lainasta, jonka Euroopan investointipankki (EIP) myönsi yhtiölle kolmivuotiseen projektiin heinäkuussa 2016. Laina myönnettiin osana EIP:n ”InnovFin - EU Finance for innovators” -ohjelmaa. Ohjelman tavoitteena on tukea innovatiivisten eurooppalaisten yhtiöiden haastavia korkean teknologian kehityshankkeita mahdollistamalla rahoituksen. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20181114005789/fi/ Aiemmin nostettujen EIP:n lainaerien avulla Mobidiag on kehittänyt valmiiksi ja kaupallistanut Novodiag® -molekyylidiagnostiikan järjestelmänsä sekä kaksi suolistoinfektioiden aiheuttajien tunnistamiseen käytettävää testiä (Novodiag® C. difficile ja Novodiag® Bacterial GE+). Viimeisen lainaerän avulla yhtiö nope
Mobidiag Receives Final €4M Tranche of €15M EIB Financing15.11.2018 09:30 | Tiedote
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for innovators” programme, an EIB initiative aimed at providing innovative and high quality companies in Europe with access to finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005786/en/ The EIB funding has already enabled Mobidiag to finalize, launch and commercialize its Novodiag® molecular diagnostic system and two assays for detection of gastrointestinal infections (Novodiag® C. difficile and Novodiag® Bacterial GE+). The final tranche will enable the Company to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system an
Highlights of China’s No. 1 High-Tech Fair CHTF 201815.11.2018 05:00 | Tiedote
The 20th China Hi-Tech Fair (CHTF 2018) is being held from November 14-18 at the Shenzhen Convention and Exhibition Center with the theme “New Development Concept for High Quality Growth.” This year’s CHTF consists of exhibitions, forums, professional meetings, supporting activities, talents exchange meetings and overseas fairs, and features advanced manufacturing, next-generation information technology, AI, life sciences, new materials, new energy, as well as integration of real economy and future industries. Here are some of the highlights of CHTF 2018: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005654/en/ International and Belt & Road Pavilion of CHTF (Photo: Business Wire) Themed areas focusing on industry hotspots The IT exhibition will present themed areas like AI, smart manufacturing, smart automotive, sports technology, big data, cloud computing, IoT and blockchain; the environmental exhibition will highlig
MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event15.11.2018 00:00 | Tiedote
MapleStory, the iconic global MMORPG from Nexon America, is bringing the first phase of its long-awaited battle with the sinister villain, the Black Mage. Between November 14 through November 28, players can take part in the “Gathering of Heroes” event to join the Maple Alliance and prepare their armies to soon combat the Black Mage. The Black Mage has long been the main antagonist behind MapleStory. His story originated with the role of bringing balance to Maple World, but turned dark as he realized the only way to save Maple World was to destroy it. Now that his seal has been broken, players will need to work together to defeat the legendary boss. The Gathering of Heroes event adds the Maple Alliance outpost, where players can hone their skills and prepare to level up in preparation of for their battle against the Black Mage, as well as adds various leveling updates. The main goal of the Alliance is to gather “Determination” and power up the holy light in the outpost to be able to fi
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 23:07 | Tiedote
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme